BIOLASE, Inc.

OTCPK:BIOL.Q Aktierapport

Börsvärde: US$274.5k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

BIOLASE Framtida tillväxt

Future kriterier kontrolleras 0/6

Vi har för närvarande inte tillräcklig analytikertäckning för att förutsäga tillväxt och intäkter för BIOLASE.

Viktig information

n/a

Tillväxttakt i vinsten

n/a

Tillväxttakt för EPS

Medical Equipment vinsttillväxt16.2%
Intäkternas tillväxttaktn/a
Framtida avkastning på eget kapitaln/a
Bevakning av analytiker

None

Senast uppdateradn/a

Senaste uppdateringarna om framtida tillväxt

Recent updates

Seeking Alpha • Aug 31

Biolase partners with dental speciality programs across U.S.

Biolase (NASDAQ:BIOL) announced strategic plan to partner with postgraduate dental specialty programs throughout North America for dentists to adopt its Waterlase technology. "We believe investing in postgraduate programs will accelerate the adoption curve and be mutually beneficial. The residents will learn the benefits of all tissue laser technology in dentistry while providing the latest in patient care," the company said. The Waterlase dental laser offers faster procedures to less invasive treatment option.
Seeking Alpha • Jul 21

BIOLASE: Ongoing Operating Losses, Capital Raises To Sustain Liquidity

BIOLASE is a name we advocate investors to steer clear of in long-only, equity focused portfolios. The company displays numerous characteristics investors are agnostic to in FY22, particularly around profitability and equity beta. BIOL's earnings model sees it print ongoing operating losses and weak FCF conversion, requiring sustained capital injections for liquidity. We've priced the stock at $4 suggesting the market has it fairly valued. We are neutral on BIOLASE, Inc. (BIOL) shares and note the company is ill-positioned to deliver capital appreciation in the coming periods. BIOL's earnings model involves razor thin gross margins that feed minimal amounts of operating income to free cash below the bottom line. Hence, it prints a series of operating losses that require continuous external capital injection in order to maintain liquidity. A review of the company's products is best left for a separate review; hence, we will take a hard data approach to gauge the investment debate. We price BIOL at $4 per share, and note it displays numerous characteristics investors are shying away from in their positioning for FY23. We rate BIOL neutral. Exhibit 1. BIOL 6-month price action Data: Updata Market factors show divergence from equity premia Investors have finally wound back the high-beta trade of FY20/21' and are paying attention to quality and value factors once more. Fundamental momentum and earnings quality are more imperative than ever. Companies with proven market fit, strong economics, and above all, defensible business models have strengthened against benchmarks whilst reducing correlations in doing so. Later we demonstrate the weakness in BIOL's earnings model. However, it's abundantly clear BIOL displays a lack of the alternative premia investors are paying a premium for in FY22. Firstly, the stock has declined in relative strength against the benchmark sharply since April, as seen below. Meanwhile, after a small blip, its equity beta has remained substantially high at 1.2 indicating it is a high-beta play that will likely to have been punished this YTD. This much is true – BIOL has caught sellers all the way from $11, posting a 59% loss since January. Exhibit 2. BIOL has weakened against the benchmark as equity beta remains high – factors investors are agnostic to in FY22 Data: Updata Unsurprisingly, the stock has also weakened against the US medical devices and health care equipment sector since equity markets began to downturn in October 2021. As seen in Exhibit 3, BIOL now trades at a 12-month low relative to the sector. As investors step up in quality and resiliency, they will look to defensible characteristics and high return on capital amid the shifting rates regime. On this, BIOL lags and hence potentially explains the relative weakness to the traditionally defensive US medtech sector. Exhibit 3. BIOL continues to weaken against US medtech & health care equipment, as investors step up in quality in the space Data: Updata Fundamental Factors Don't Stack Up Q1 FY22 sales came in at ~$10 million, ~25% YoY growth. Performance was underlined by a 43% YoY gain to US laser systems and a 35% YoY gain to BIOLASE specific procedures. International turnover also grew 15% and have been steady for the last few quarters. On a marginal basis, the company lifted gross margin 13 percentage points to 47% – above pre-pandemic gross margin of 34%. This is still razor thin however, and leaves little headroom down the P&L for margin elasticity. On this, management notes it successfully passed costs through in Q1, printing operating expenses of ~$9 million, in line from last year. To achieve is guided 10% YoY revenue growth in FY22/23', BIOL has what it calls a 3-pronged strategy that's been in situ since 2021. Chief to the first 'prong' is specialist adoption of the laser technology. To this effect, BIOL formed an academy to market the dental lasers amongst orthodontists, endodontists and periodontists back in 2021. It did this to hopefully drive up the acceleration of new accounts, management said on the Q1 earnings call. Its second 'prong' is more of a speculative growth play at the US general practitioner dentist ("GPD") market, by our estimate. It notes there are ~150,000 of these generalists in the US, and makes some very generous assumptions around its ability to penetrate this segment. Per CEO John Beaver on the Q1 earnings call, "[i]f an additional 5% of GPDs adopted our laser in the US, it would generate $225 million in laser revenue, not including consumables," on the Q1 earnings call. Again, these are very generous assumptions around its addressable market that haven't yet begun to materialise. To get to $225 million from an additional 5% of GPD adoption, BIOL says it expanded its Waterlase Exclusive Trial program. This lets GPDs utilise the system in their office for ~45 days. Included is 2 days of in-person training and mentor support, all at no extra cost. Afterwards, the clinician is prompted to buy the laser. Firstly this is a timely and costly way of trying to convert GPDs. It takes longer than 1 30 day payment cycle and there's no incentive structure to use the device on trial. Moreover, conversion has been light on these events to date. It held 30 in FY21 and 12 so far this YTD. Each had 4–8 GPDs participate, management said, 9.5%–19% participation rate. The third 'prong' is driving the adoption of its lasers to corporate dentists. It has ongoing trials with 80% of the largest DSOs in the US, which targets new graduates as many new dentists are employed by the DSOs straight from dental school. BIOL hopes to educate them on using the lasers, and try and make lasers an "essential part of their practice moving forward". Hence, when out in practice, they might be drawn to BIOL lasers. Again, fraught with assumption, by estimate, and it relies on the premise these dentists will prefer BIOL lasers in the first place. There's no evidence to suggest this will be the case. In that vein, BIOL's profitability characteristics are an equity risk looking ahead. Investors have turned away from rewarding top-line growth in FY22 and are rewarding bottom-line fundamentals and profitability instead. Whilst it continues to build its top line at ~25% YoY, this doesn't pull through the P&L to earnings and FCF. As such, BIOL has printed a series of operating losses since FY15 to date, whilst realizing a negative FCF yield across this entire time span. Moreover, sales were extremely lumpy pre-Covid, and haven't grown back past these levels. Exhibit 4. Series of lumpy sales performance and operating losses sees weak FCF conversion
Seeking Alpha • Jul 01

BIOLASE amends senior secured term loan with SWK Funding

BIOLASE (NASDAQ:BIOL) has amended its senior secured term loan with SWK Funding LLC by extending the interest-only period of the loan by two quarters to November 2023 and reduces the minimum Consolidated Unencumbered Liquid Assets from $7,500,000 to $5,500,00. The company used a portion of the proceeds from its recent equity offering to prepay $1M of the outstanding loan balance. John Beaver, President and Chief Executive Officer of BIOLASE said, "This prepayment and amendment will result in lower interest expense while also increasing the Company's liquidity."
Seeking Alpha • Mar 21

BIOLASE: Bad News Across The Board - Sell

Company reports Q4 results in-line with preliminary numbers and provides a rather disappointing outlook. Profitability target delayed by another year. Muted growth in combination with the decision to keep pricing steady likely to result in another year of material cash usage. On the conference call, management affirmed its intent to conduct a reverse stock split before the May 23 deadline. With profitability delayed by another year and the likely requirement to raise additional capital in 2023, investors should consider selling existing positions ahead of the upcoming reverse stock split.
Analysartikel • Feb 24

Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Jan 11

BIOLASE - Speculative Buy After Strong Preliminary Q4 Results

Company releases very strong preliminary Q4 top-line numbers with revenues now eclipsing pre-COVID numbers. Despite solid execution, shares have retreated by 80% from recent highs as investors remain wary of ongoing cash usage and a potential reverse stock split to regain Nasdaq listing compliance. Biolase continues to burn sizeable amounts of cash with adjusted EBITDA profitability not expected before Q4/FY2022. Shares are trading at bargain levels at just 0.7x EV/Revenue. Despite poor market sentiment, highly speculative investors should consider a rebound trade in the shares given management's solid execution, bargain valuation and expectations for EBITDA profitability at the end of the year.
Seeking Alpha • Nov 24

BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors

Company continues to outperform expectations as sales and margins recover from last year's COVID-related setback. Despite solid execution, shares have retreated by more than 70% from recent highs as investors remain wary of a potential reverse stock split to regain Nasdaq listing compliance. Biolase continues to burn sizeable amounts of cash with adjusted EBITDA profitability not expected before Q4/FY2022. Stock looks cheap from a fundamental perspective, trading at just 1.25x EV/Revenue. On Tuesday, Biolase announced another 180-day Nasdaq extension and improved credit terms with its primary lender thus providing a major catalyst for the beaten down shares but only the most speculative investors/traders you consider scaling into the shares at current levels given ongoing cash burn and the likely requirement to execute a reverse stock split next year.

I detta avsnitt presenterar vi vanligtvis intäkts- och vinsttillväxtprognoser baserade på professionella analytikers konsensusuppskattningar för att hjälpa investerare att förstå företagets förmåga att generera vinst. Men eftersom BIOLASE inte har tillhandahållit tillräckligt med tidigare data och inte har någon analytikerprognos kan dess framtida resultat inte beräknas på ett tillförlitligt sätt genom att extrapolera tidigare data eller använda analytikerförutsägelser.

Detta är en ganska sällsynt situation eftersom 97% av de företag som omfattas av SimplyWall St har tidigare finansiella uppgifter.

Prognoser för vinst- och omsättningstillväxt

OTCPK:BIOL.Q - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
9/30/202446-16-14-13N/A
6/30/202446-27-12-12N/A
3/31/202449-38-15-14N/A
12/31/202349-38-15-14N/A
9/30/202350-42-19-17N/A
6/30/202351-38-25-21N/A
3/31/202349-30-28-24N/A
12/31/202248-29-30-27N/A
9/30/202247-24-28-24N/A
6/30/202244-19-22-21N/A
3/31/202241-14-19-18N/A
12/31/202139-17-17-17N/A
9/30/202135-18-15-15N/A
6/30/202132-32-14-13N/A
3/31/202126-36-15-15N/A
12/31/202023-34-13-13N/A
9/30/202024-32-16-16N/A
6/30/202027-20-16-15N/A
3/31/202032-19-12-12N/A
12/31/201938-18-13-13N/A
9/30/201941-21-12-12N/A
6/30/201943-20-13-12N/A
3/31/201946-21-15-14N/A
12/31/201846-22-15-14N/A
9/30/201846-18-15-15N/A
6/30/201846-18N/A-16N/A
3/31/201846-22N/A-18N/A
12/31/201747-21N/A-18N/A
9/30/201748-21N/A-17N/A
6/30/201750-22N/A-15N/A
3/31/201752-17N/A-11N/A
12/31/201652-18N/A-11N/A
9/30/201652-16N/A-10N/A
6/30/201650-16N/A-13N/A
3/31/201648-19N/A-15N/A
12/31/201548-20N/A-18N/A
9/30/201547-22N/A-21N/A
6/30/201548-20N/A-24N/A
3/31/201547-19N/A-21N/A
12/31/201447-19N/A-16N/A
9/30/201449-17N/A-12N/A
6/30/201449-18N/A-7N/A
3/31/201453-14N/A-9N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: Otillräcklig data för att avgöra om BIOL.Q s prognostiserade vinsttillväxt ligger över sparkvoten ( 2.8% ).

Resultat vs marknad: Otillräcklig data för att avgöra om BIOL.Q s intäkter förväntas växa snabbare än marknaden för US

Höga tillväxtresultat: Otillräcklig data för att avgöra om BIOL.Q s intäkter förväntas växa avsevärt under de kommande 3 åren.

Intäkt vs marknad: Otillräcklig data för att avgöra om BIOL.Q s intäkter förväntas växa snabbare än marknaden för US.

Hög tillväxtintäkter: Otillräcklig data för att avgöra om intäkterna från BIOL.Q förväntas växa snabbare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: Otillräcklig data för att avgöra om BIOL.Q s avkastning på eget kapital förväntas bli hög om tre år

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2025/03/12 23:43
Aktiekurs vid dagens slut2025/03/12 00:00
Intäkter2024/09/30
Årlig intjäning2023/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

BIOLASE, Inc. bevakas av 8 analytiker. 0 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Edward WooAscendiant Capital Markets LLC
Bruce JacksonBenchmark Company
Kyle BauserColliers Securities